(United States, Nevada, Las Vegas), DelveInsight’s, “Cystic Fibrosis – Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Cystic Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cystic Fibrosis Pipeline Report
-
Over 75+ companies and 80+ pipeline drugs in Cystic Fibrosis are in various stages of development, and their anticipated acceptance in the Cystic Fibrosis market would significantly increase market revenue.
-
Leading Cystic Fibrosis companies developing novel drug candidates to improve the Cystic Fibrosis treatment landscape include Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, AbbVie, AstraZeneca and others.
-
Promising Cystic Fibrosis pipeline therapies in various stages of development include OligoG, Ensifentrine, MRT5005, CB280, and others.
Cystic Fibrosis Overview
Cystic fibrosis is a progressive, genetic disease that causes long-lasting lung infections and limits the ability to breathe over time. More than 30,000 children and adults in the United States have Cystic Fibrosis(70,000 worldwide) and Cystic Fibrosis affects people of every racial and ethnic group. In people with Cystic Fibrosis, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause the CFTR protein to become dysfunctional. When the protein is not working correctly, it’s unable to help move chloride — a component of salt — to the cell surface. People with CF can have a variety of symptoms, including Very salty-tasting skin, persistent coughing, at times with phlegm, frequent lung infections including pneumonia or bronchitis, wheezing or shortness of breath, poor growth or weight gain in spite of a good appetite, frequent greasy, bulky stools or difficulty with bowel movements, nasal polyps, chronic sinus infections and many more. Cystic fibrosis is a complex disease. The types of symptoms and how severe they are can differ widely from person to person.
Cystic Fibrosis Pipeline Analysis: Drug Profile
OligoG: Algi Pharma
OligoG is formulated as a dry powder for inhalation and is AlgiPharma’s lead drug candidate. It is an alginate oligosaccharide derived from seaweed and is a new class of drug which is modulating mucus and normalizes mucus rheology. It is being developed to help people with cystic fibrosis clear mucus from their lungs. It is anticipated that OligoG may help to slow the progression of the disease. OligoG has been shown to disrupt the infectious biofilm often present in the lungs of individuals with CF. This biofilm disruption is believed to improve antibiotic effectiveness by increasing the exposure of bacteria to antibiotics. It is in the Phase 2 stage of development for the treatment of Cystic Fibrosis.
Discover more about the emerging Cystic Fibrosis drugs @ Cystic Fibrosis Treatment Drugs
Cystic Fibrosis Pipeline Therapies and Key Companies
-
OligoG: Algi Pharma
-
Ensifentrine: Verona Pharma
And many others
Cystic Fibrosis Pipeline Therapeutics Assessment
Phases
Route of Administration
Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Cystic Fibrosis Pipeline Report
-
Coverage: Global
-
Key Cystic Fibrosis Companies: Algi Pharmaceuticals, Verona Pharma, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, AbbVie, AstraZeneca
-
Key Cystic Fibrosis Pipeline Therapies: OligoG, Ensifentrine, and other Find out more about the Cystic Fibrosis treatment options in development @ Cystic Fibrosis Clinical Trials
Table of Contents
1. Cystic Fibrosis Introduction
2. Cystic Fibrosis Executive Summary
3. Cystic Fibrosis Overview
4. Cystic Fibrosis Pipeline Therapeutics
5. Cystic Fibrosis Late-Stage Products (Phase III)
6. Cystic FibrosisMid-Stage Products (Phase II)
7. Cystic Fibrosis Early Stage Products (Phase I/II)
8. Cystic Fibrosis Preclinical Stage Products
9. Cystic Fibrosis Discovery Stage Products
10. Cystic Fibrosis Therapeutic Assessment
11. Cystic Fibrosis Inactive Products
12. Cystic Fibrosis Collaborations Assessment- Licensing / Partnering / Funding
13. Cystic Fibrosis Unmet Needs
14. Cystic Fibrosis Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services